Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

The PEGylation Technology

CIMZIA is the only PEGylated anti-TNF1-5

A molecule called polyethylene glycol (PEG) is added to the Fab', enabling dosing only once every 4 weeks.1,6

Stable dosing

  • Stable serum levels were achieved with no dose escalation in clinical trials*2,6
  • Q4-week subcutaneous dosing*2

*Initial dose at Weeks 0, 2, and 4, then every 4 weeks as maintenance therapy.

References:

  1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
  2. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
  3. Humira [prescribing information]. North Chicago, IL: Abbott Laboratories; 2008.
  4. Remicade [prescribing information]. Malvern, PA: Centocor, Inc.;2007.
  5. Schreiber S, Panes J, Mason D, Lichtenstein G, Sandborn WJ. Sustained efficacy and tolerability of certolizumab pegol over 18 months: data from PRECiSE 2 and its extension studies (PRECiSE 3 and 4). Poster presented at: American College of Gastroenterology Annual Meeting; October 12-17, 2007; Philadelphia, PA.
  6. Chapman AP. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev. 2002;54:531-545.
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA